Savara Q3 Loss Widens to $43.0M as MOLBREEVI PDUFA Nears November 22
SVRA sits 31% above its 52-week low of $3.86.
Summary
Savara posted a $43.0 million Q3 loss on heavier commercial spending and ended September with $129.6 million in cash and investments. The FDA's MOLBREEVI decision date of November 22, 2026 now sits days away and gates both the $75 million RTW royalty payment and $75 million of additional Hercules borrowing.
Key Events · Earnings and Guidance · SVRA
-
Q3 Loss Widens on Commercial Build-Out
Net loss was $42.989 million for the three months ended September 30, 2026 versus $29.561 million a year earlier; G&A rose 92.6% to $18.5 million and R&D rose 21.1% to $24.9 million.
-
Cash Falls to $129.6 Million
Cash and cash equivalents of $29.8 million plus short-term investments of $99.8 million at September 30, 2026, against $105.257 million of operating cash burn in the first nine months.
-
PDUFA Date Set for November 22, 2026
The FDA extended the MOLBREEVI BLA review by three months after treating the company's responses as a major amendment; the target action date is now November 22, 2026.
-
Approval Unlocks $150 Million of Funding
FDA approval on or before March 31, 2027 triggers the $75.0 million RTW royalty purchase payment, and the amended Hercules facility adds up to $75 million of post-approval tranches.
Analysis · SVRA · Life Sciences
Savara's quarterly loss widened to $43.0 million from $29.6 million a year ago, driven by a 92.6% jump in G&A to $18.5 million as it builds a commercial team ahead of a potential MOLBREEVI launch. Nine-month operating cash burn rose to $105.3 million from $76.0 million, leaving $129.6 million in cash and short-term investments at quarter end. The company says that funds at least twelve months of operations, but the FDA's PDUFA target action date of November 22, 2026 is now days away and is the event that determines whether the $75 million RTW royalty payment and the $75 million of post-approval Hercules tranches become available. A rejection or further delay would leave a company burning roughly $35 million a quarter with a much thinner funding path.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SVRA was trading at $5.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $3.86 to $7.01. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.